Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.
Jun 28, 2016
0
15
(AP) -- The Food and Drug Administration says Merck's cholesterol drug Vytorin helps reduce heart attack, stroke and related problems in patients with kidney disease, a potential new use for the blockbuster drug.
Oct 31, 2011
0
0
Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie.
Dec 19, 2014
0
0
Whether it's a 30-year-old woman who has no time for doctor's visits, or an embarrassed teen who doesn't want to tell her parents she wants to use birth control, Nurx brings the doctor's visit to their palms and eliminates ...
Sep 1, 2017
0
8
General practitioners in England dramatically decreased their prescriptions of the combined contraceptive pill during the first COVID-19 lockdown, and these rates have not recovered since, according to new research published ...
Apr 27, 2022
0
2
A pill combining low doses of three blood pressure-lowering medications significantly increased the number of patients reaching blood pressure targets compared with usual care, researchers reported at the American College ...
Mar 12, 2018
0
2
Women taking the pill may have been alarmed by headlines today linking the oral contraceptive with breast cancer. But for women thinking of chucking their packet in the bin, it might reassure you to know that we don't ...
Aug 5, 2014
0
0
Patients with hepatitis C have yet another advanced treatment option, as the Food on Drug Administration on Thursday approved a new once-a-day pill developed by drugmaker Merck.
Jan 28, 2016
0
2
Almost 50% of pregnancies in the U.S. are still unplanned or mistimed, even though the first birth control pill was sold almost 60 years ago.
Oct 8, 2019
0
15
People are much more likely to take heart medicines if they're combined in one pill, according to a late-breaking clinical trial presented at the American Heart Association's Scientific Sessions 2012.
Nov 6, 2012
0
0
